1887
  1. Home
  2. A-Z Publications
  3. Journal of Emergency Medicine, Trauma and Acute Care
  4. Volume 2022, Issue 5
  5. Article
Volume 2022, Issue 5
  • ISSN: 1999-7086
  • EISSN: 1999-7094

Abstract

Mortality associated with COVID-19 varies in various reports, with minimal data on the factors associated with in-hospital mortality.

To identify the risk factors for in-hospital death of patients with COVID-19 in an intensive care unit (ICU) in Qatar.

A retrospective observational study of patients confirmed with COVID-19 and admitted to the medical-surgical ICU at The Cuban Hospital was carried out from April 12, 2020, to September 12, 2020. From patients’ electronic medical records, demographic, clinical, laboratory, and radiology data was collected.

275 patients with COVID-19 were admitted to the ICU, and 32 (11.6%) died. 56.1% were men, and the mean age was 52.2 years. According to the univariate analysis, patients with diabetes mellitus with end-organ damage (37.5%), cardiovascular disease (31.3%), dementia (9.4%), kidney disease (28.1%), chronic obstructive pulmonary disease (31.3%), and higher Charlson index had higher mortality. According to the multivariate analysis, an increase of mortality risk by 9% was observed for each additional year of age (Odds ratio [OR] 1.09; 95% confidence interval [CI] 1.04–1.14), patients on mechanical ventilation (OR 27.33; 95% CI 3.21–232.46), and those with adult respiratory distress (OR 15.85; 95% CI 1.45–172.82) and elevated procalcitonin (OR 7.30; 95% CI 1.25–42.58), and the PiO/FiO ratio between 100 and 299 decreased the risk of death by 92% (OR 0.08; 95% CI 0.02–0.39), in comparison to a PiO/FiO ratio less than 100 or greater than 300.

The study provides evidence about the risk of mortality among COVID-19 patients with a significant contribution of age, respiratory failure, and co-infections.

© 2022 Jimenez, Garcell, García, licensee HBKU Press.
Loading

Article metrics loading...

/content/journals/10.5339/jemtac.2022.36
2022-11-30
2024-04-26
Loading full text...

Full text loading...

/deliver/fulltext/jemtac/2022/5/jemtac.2022.36.html?itemId=/content/journals/10.5339/jemtac.2022.36&mimeType=html&fmt=ahah

References

  1. Tang D, Comish P, Kang R. The hallmarks of COVID-19 disease. PLoS Pathog. 2020; 16:(5):e1008536. doi: 10.1371/journal.ppat.1008536.
     [Google Scholar]
  2. Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia – A systematic review, meta-analysis, and meta-regression. Diabetes MetabSyndr. 2020; 14:(4):395–403. doi: 10.1016/j.dsx.2020.04.018.
     [Google Scholar]
  3. Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practi-cal considerations. Diabetes MetabSyndr. 2020; 14:(4):303–10. doi: 10.1016/j.dsx.2020.04.004.
     [Google Scholar]
  4. Pranata R, Huang I, Lim MA, Wahjoepramono EJ, July J. Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19-systematic review, meta-analysis, and meta-regression. J Stroke Cerebrovasc Dis. 2020; 29:(8):104949. doi: 10.1016/j.jstrokecerebrovasdis.2020.104949.
     [Google Scholar]
  5. Pranata R, Lim MA, Huang I, Raharjo SB, Lukito AA. Hypertension is associated with increased mortality and sever-ity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression. J Renin Angiotensin Aldosterone Syst. 2020; 21:(2):1470320320926899. doi: 10.1177/1470320320926899.
     [Google Scholar]
  6. Alqahtani JS, Oyelade T, Aldhahir AM, et al. Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: A rapid systematic review and meta-analysis. PLoS One. 2020; 15:(5):e0233147. doi: 10.1371/journal.pone.0233147.
     [Google Scholar]
  7. Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and mortality among black patients and white pa-tients with Covid-19. N Engl J Med. 2020; 382:(26):2534–43. doi: 10.1056/NEJMsa2011686.
     [Google Scholar]
  8. Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. Lancet. 2020; 395:(10229):1014–5. doi: 10.1016/S0140-6736(20)30633-4.
     [Google Scholar]
  9. Wang D, Yin Y, Hu C, et al. Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China. Crit Care. 2020; 24:(1):188. doi: 10.1186/s13054-020-02895-6.
     [Google Scholar]
  10. Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York city: a prospective cohort study. Lancet. 2020; 395:(10239):1763–70. doi: 10.1016/S0140-6736(20)31189-2.
     [Google Scholar]
  11. Chilimuri S, Sun H, Alemam A, et al. Predictors of mortality in adults admitted with COVID-19: Retrospective cohort study from New York city. West J Emerg Med. 2020; 21:(4):779–84. doi: 10.5811/westjem.2020.6.47919.
     [Google Scholar]
  12. Sousa GJB, Garces TS, Cestari VRF, Florêncio RS, Moreira TMM, Pereira MLD. Mortality and survival of COVID-19. Epidemiol Infect. 2020; 148::e123. doi: 10.1017/S0950268820001405.
     [Google Scholar]
  13. Huang I, Pranata R, Lim MA, Oehadian A, Alisjahbana B. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Ther Adv Respir Dis. 2020; 14::1753466620937175. doi: 10.1177/1753466620937175.
     [Google Scholar]
  14. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020; 55:(5):105954. doi: 10.1016/j.ijantimicag.2020.105954.
     [Google Scholar]
  15. Tian W, Jiang W, Yao J, et al. Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis. J Med Virol. 2020; 92:(10):1875–83. doi: 10.1002/jmv.26050.
     [Google Scholar]
  16. Ghonimi TAL, Alkad MM, Abuhelaiqa EA, Othman MM, Elgaali MA, Ibrahim RAM, Joseph SM, Al-Malki HA, Hamad AI. Mortality and associated risk factors of COVID-19 infection in dialysis patients in Qatar: A nationwide cohort study. PLoS One. 2021; 16:(7):e0254246. doi: 10.1371/journal.pone.0254246.
     [Google Scholar]
  17. Alwahaibi N, Al Maskari M, Al Dhahli B, Al Issaei H, Al-Jaaidi Shadia Al Bahlani S. One-year review of COVID-19 in the Arab world. Qatar Med J. 2021; 2021:(3):66. doi: 10.5339/qmj.2021.66.
     [Google Scholar]
  18. Worldometer coronavirus data. [Internet] [Access May 5, 2022] Available from: https://www.worldometers.info/coronavirus/
     [Google Scholar]
  19. Moreno R, Vincent JL, Matos R, Mendonça A, Cantraine F, Thijs L, et al. The use of maximum SOFA Score to quantify organ dysfunction/failure in intensive care. Results of a prospective, multicentre study. Intensive Care Medicine. 1999; 25:(7):686–96. doi: 10.1007/s001340050931.
     [Google Scholar]
  20. Cabré L, Mancebo J, Solsona JF, Saura P, Gich I, Blanch L, et al., Bioethics Working Group of the SEMICYUC. Multicenter study of the multiple organ dysfunction syndrome in intensive care units: the usefulness of Se-quential Organ Failure Assessment scores in decision making. Intensive Care Med. 2005; 31:(7):927–33. doi: 10.1007/s00134-005-2640-2.
     [Google Scholar]
  21. Knaus WA, Draper EA, Wagner DP, Zimmermann JE. APACHE-II: a severity of disease classification system. Crit Care Med. 1985; 13:(10):819–29.
     [Google Scholar]
  22. Draper EA, Wagner DP. Acute physiology and chronic health evaluation (APACHE-II) and medicare reinburse-ment. Health Care Financ Rev. 1984;Suppl.:91–105.
     [Google Scholar]
  23. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitu-dinal studies: development and validation. J Chronic Dis. 1987; 40::373–83. doi: 10.1016/0021-9681(87)90171-8.
     [Google Scholar]
  24. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity: a critical review of available methods. J Clin Epidemiol. 2003; 56::221–9. doi: 10.1016/s0895-4356(02)00585-1.
     [Google Scholar]
  25. Khamis F, Memish Z, Bahrani MA, Dowaiki SA, Pandak N, Bolushi ZA, et al. Prevalence and predictors of in-hospital mortality of patients hospitalized with COVID-19 infection. J Infect Public Health. 2021; 14:(6):759–65. doi: 10.1016/j.jiph.2021.03.016.
     [Google Scholar]
  26. Dessie ZG, Zewotir T. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 stud-ies and 423,117 patients. BMC Infect Dis. 2021; 21:(1):855. doi: 10.1186/s12879-021-06536-3.
     [Google Scholar]
  27. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel corona-virus in Wuhan, China. Lancet. 2020; 395:(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5.
     [Google Scholar]
  28. Gao YD, Ding M, Dong X, Zhang JJ, Azkur AK, Azkur D, et al. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy. 2021; 76:(2):428–55. doi: 10.1111/all.14657.
     [Google Scholar]
  29. Kronbichler A, Effenberger M, Eisenhut M, Lee KH, Shin JI. Seven recommendations to rescue the patients and reduce the mortality from COVID-19 infection: An immunological point of view. Autoimmun Rev. 2020; 19:(7):102570. doi: 10.1016/j.autrev.2020.102570.
     [Google Scholar]
  30. Zhou J, He W, Liang J, Wang L, Yu X, Bao M, Liu H. Association of Interleukin-6 Levels with Morbidity and Mortal-ity in Patients with Coronavirus Disease 2019 (COVID-19). Jpn J Infect Dis. 2021; 74:(4):293-298. doi: 10.7883/yoken.JJID.2020.463.
     [Google Scholar]
  31. Andreen N, Andersson L-M, Sundell N, Gustavsson L, Westin J. Mortality of COVID-19 is associated with comor-bidity in patients with chronic obstructive pulmonary disease. Infect Dis (Lond). 2022; 54:(7):508–13. doi: 10.1080/23744235.2022.2050422.
     [Google Scholar]
  32. Halpin DMG, Vogelmeier CF, Agusti AA. COPD & COVID-19. Arch Bronconeumol (Engl Ed). 2021; 57:(3):162–4. doi: 10.1016/j.arbr.2021.01.004.
     [Google Scholar]
  33. Brant LCC, Pinheiro PC, Ribeiro ALP, Machado IE, Correa PRL, Santos MR, et al. Cardiovascular mortality during the COVID-19 pandemics in a large Brazilian city: A comprehensive analysis. Glob Heart. 2022; 17:(1):11. doi: 10.5334/gh.1101.
     [Google Scholar]
  34. Chung MK, Zidar DA, Bristow MR, Cameron SJ, Chan T, Harding 3rd CV, et al. COVID-19 and cardiovascular disease: From bench to bedside. Circ Res. 2021; 128:(8):1214–36. doi: 10.1161/circresaha.121.317997.
     [Google Scholar]
  35. Aggarwal G, Cheruiyot I, Aggarwal S, Wong J, Lippi G, Lavie CJ, et al. Association of cardiovascular disease with coronavirus disease 2019 (COVID-19) severity: A meta-analysis. Curr Probl Cardiol. 2020; 45:(8):100617. doi: 10.1016/j.cpcardiol.2020.100617.
     [Google Scholar]
  36. Cai R, Zhang J, Zhu Y, Liu L, Liu Y, He Q. Mortality in chronic kidney disease patients with COVID-19: a system-atic review and meta-analysis. Int UrolNephrol. 2021; 53:(8):1623–9. doi: 10.1007/s11255-020-02740-3.
     [Google Scholar]
  37. Betjes MG. Immune cell dysfunction and inflammation in end-stage renal disease. Nat Rev Nephrol. 2013; 9:(5):255–65. doi: 10.1038/nrneph.2013.44.
     [Google Scholar]
  38. Jdiaa SS, Mansour R, El Alayli A, Gautam A, Thomas P, Mustafa RA. COVID-19 and chronic kidney disease: an updated overview of reviews. J Nephrol. 2022; 35:(1):69–85. doi: 10.1007/s40620-021-01206-8.
     [Google Scholar]
  39. Paharia PT. White blood cell count as a prognostic indicator of COVID-19. News Medical [Internet]. 2022. [Accessed May 03, 2022]. Available from: https://www.news-medical.net/news/20220223/White-blood-cell-count-as-a-prognostic-indicator-of-COVID-19.aspx
     [Google Scholar]
  40. Twe CW, Khoo DKY, Law KB, Nordin NSBA, Sathasivan S, Lim KC, et al. The role of procalcitonin in predicting risk of mechanical ventilation and mortality among moderate to severe COVID-19 patients. BMC Infect Dis. 2022; 22:(1):378. doi: 10.1186/s12879-022-07362-x.
     [Google Scholar]
  41. Allwood BW, Koegelenberg CF, Ngah VD, Sigwadhi LN, Irusen EM, Lalla U, et al. Predicting COVID-19 outcomes from clinical and laboratory parameters in an intensive care facility during the second wave of the pandemic in South Af-rica. IJID Regions, 2022; 3::242–7. doi: 10.1016/j.ijregi.2022.03.024.
     [Google Scholar]
  42. Wei XS, Wang X, Ye LL, Niu YR, Peng WB, Wang ZH, et al. Pleural effusion as an indicator for the poor prognosis of COVID-19 patients. Int J Clin Pract. 2021; 75:(6):e14123. doi: 10.1111/ijcp.14123.
     [Google Scholar]
  43. Tong-Minh K, van der Does Y, Engelen S, de Jong E, Ramakers C, Gommers D, et al. High procalcitonin levels associated with increased intensive care unit admission and mortality in patients with a COVID-19 infection in the emer-gency department. BMC Infect Dis. 2022; 22:(1):165. doi: 10.1186/s12879-022-07144-5.
     [Google Scholar]
  44. Xu JB, Xu C, Zhang RB, Wu M, Pan CK, Li XJ, et al. Associations of procalcitonin, C-reaction protein and neu-trophil-to-lymphocyte ratio with mortality in hospitalized COVID-19 patients in China. Sci Rep. 2020; 10:(1):15058. doi: 10.1038/s41598-020-72164-7.
     [Google Scholar]
  45. Tom J, Bao M, Tsai L, Qamra A, Summers D, Carrasco-Triguero M, et al. Prognostic and predictive biomarkers in patients with coronavirus disease 2019 treated with Tocilizumab in a randomized controlled trial. Crit Care Med. 2022; 50:(3):398–409. doi: 10.1097/CCM.0000000000005229.
     [Google Scholar]
  46. Rathore SS, Rojas GA, Sondhi M, Pothuru S, Pydi R, Kancherla N, et al. Myocarditis associated with Covid-19 disease: A systematic review of published case reports and case series. Int J Clin Pract. 2021; 75:(11):e14470. doi: 10.1111/ijcp.14470.
     [Google Scholar]
  47. Rathore SS, Hussain N, Manju AH, Wen Q, Tousif S, Avendaño-Capriles CA, et al. Prevalence and clin-ical outcomes of pleural effusion in COVID-19 patients: A systematic review and meta-analysis. J Med Virol. 2022; 94:(1):229–39. doi: 10.1002/jmv.27301.
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/jemtac.2022.36
Loading
Retrospective study of risk factors for mortality in critically ill patients with COVID-19
Journal of Emergency Medicine, Trauma and Acute Care 2022, 36 (2022); https://doi.org/10.5339/jemtac.2022.36
/content/journals/10.5339/jemtac.2022.36
/content/journals/10.5339/jemtac.2022.36
Loading

Data & Media loading...

Keyword(s): COVID-19, critical care unit, mortality, Qatar and risk factors

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error